ArticleCureus2026
Pancreatic Collision Tumor Composed of Solid Pseudopapillary Neoplasm and Well-Differentiated Neuroendocrine Tumor: Diagnostic Challenges and Classification Considerations.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collision tumors are uncommon neoplasms composed of two histologically distinct tumor populations occurring within the same anatomic site while maintaining separate boundaries. Pancreatic collision tumors composed of solid pseudopapillary neoplasm (SPN) and well-differentiated pancreatic neuroendocrine tumor (PanNET) are rare and may be diagnostically challenging because these entities can show overlapping morphologic and immunophenotypic features and may radiographically present as a single lesion. A 41-year-old woman presented with left upper quadrant abdominal pain and was found to have a pancreatic head mass. Fine-needle aspiration favored SPN, and the patient underwent extended pancreaticoduodenectomy. Histologic examination demonstrated a 3.7 cm SPN and an adjacent 0.6 cm World Health Organization grade 1 PanNET, separated by an abrupt interface without appreciable intermingling. Immunohistochemistry showed nuclear β-catenin and cyclin D1 expression in the SPN, while the PanNET showed diffuse chromogranin and INSM1 expression with retained membranous E-cadherin. Synaptophysin was positive in both tumors, highlighting a diagnostic pitfall. Eighteen lymph nodes were negative for metastatic disease, and both tumors were confined to the pancreas. This case represents the fourth reported pancreatic SPN-WDNET collision tumor and highlights important diagnostic and classification challenges in pancreatic neoplasms that demonstrate dual differentiation. Because SPNs may exhibit partial neuroendocrine differentiation, neuroendocrine marker positivity alone should not be used to establish a diagnosis of WDNET in the setting of SPN. Instead, accurate classification requires careful integration of histomorphology and complementary immunophenotypic findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.